SEARCH

SEARCH BY CITATION

References

  • Adam S.S., Key N.S. & Greenberg C.S. (2009) D-dimer antigen: current concepts and future prospects. Blood 113, 28782887.
  • Baglin T. (2005) The measurement and application of thrombin generation. British Journal of Haematology 130, 653661.
  • Baglin T. (2010) Unravelling the thrombophilia paradox: from hypercoagulability to the prothrombotic state. Journal of Thrombosis and Haemostasis 8, 228233.
  • Baglin T.P., Keeling D.M. & Watson H.G. (2006) Guidelines on oral anticoagulation (warfarin): third edition–2005 update. British Journal of Haematology 132, 277285.
  • Baglin C., Brown K., Luddington R. & Baglin T. (1998) Risk of recurrent venous thromboembolism in patients with the factor V Leiden (FVR506Q) mutation: effect of warfarin and prediction by precipitating factors. East Anglian Thrombophilia Study Group. British Journal of Haematology 100, 764768.
  • Baglin T., Luddington R., Brown K. & Baglin C. (2003) Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 362, 523526.
  • Baglin T., Palmer C., Luddington R. & Baglin C. (2008) Unprovoked recurrent venous thrombosis: prediction by D-dimer and clinical risk factors. Journal of Thrombosis and Haemostasis 6, 577582.
  • Baglin T., Gray E., Greaves M., Hunt B.J., Keeling D., Machin S., Mackie I., Makris M., Nokes T., Perry D., Tait R.C., Walker I. & Watson H. (2010) Clinical guidelines for testing for heritable thrombophilia. British Journal of Haematology 149, 209220.
  • Besser M., Baglin C., Luddington R., van Hylckama Vlieg A. & Baglin T. (2008) High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. Journal of Thrombosis and Haemostasis 6, 17201725.
  • Bezemer I.D., Bare L.A., Doggen C.J., Arellano A.R., Tong C., Rowland C.M., Catanese J., Young B.A., Reitsma P.H., Devlin J.J. & Rosendaal F.R. (2008) Gene variants associated with deep vein thrombosis. Journal of the American Medical Association 299, 13061314.
  • Christiansen S.C., Cannegieter S.C., Koster T., Vandenbroucke J.P. & Rosendaal F.R. (2005) Thrombophilia, clinical factors, and recurrent venous thrombotic events. Journal of the American Medical Association 293, 23522361.
  • Coppens M., Reijnders J.H., Middeldorp S., Doggen C.J. & Rosendaal F.R. (2008) Testing for inherited thrombophilia does not reduce recurrence of venous thrombosis. Journal of Thrombosis and Haemostasis 6, 14741477.
  • Cosmi B., Legnani C., Tosetto A., Pengo V., Ghirarduzzi A., Testa S., Prisco D., Poli D., Tripodi A., Marongiu F. & Palareti G. (2010) Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study. Blood 115, 481488.
  • Cushman M., O’Meara E.S., Folsom A.R. & Heckbert S.R. (2009) Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology. Blood 114, 28782883.
  • De Stefano V., Simioni P., Rossi E., Tormene D., Za T., Pagnan A. & Leone G. (2006) The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C and protein S. Haematologica 91, 695698.
  • Dempfle C.E. (2005) Validation, calibration, and specificity of quantitative D-dimer assays. Semininars in Vascular Medicine 5, 315320.
  • Douketis J., Tosetto A., Marcucci M., Baglin T., Cushman M., Eichinger S., Palareti G., Poli D., Tait R.C. & Iorio A. (2010) Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Annals of Internal Medicine 153, 523531.
  • Eichinger S., Hron G., Kollars M. & Kyrle P.A. (2008) Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer. Clinical Chemistry 54, 20422048.
  • Gadisseur A.P., Christiansen S.C., Van Der Meer F.J. & Rosendaal F.R. (2007) The quality of oral anticoagulant therapy and recurrent venous thrombotic events in the Leiden Thrombophilia Study. Journal of Thrombosis and Haemostasis 5, 931936.
  • Greaves M. & Baglin T. (2000) Laboratory testing for heritable thrombophilia: impact on clinical management of thrombotic disease. British Journal of Haematology 109, 699703.
  • Greaves M., Cohen H., MacHin S.J. & Mackie I. (2000) Guidelines on the investigation and management of the antiphospholipid syndrome. British Journal of Haematology 109, 704715.
  • Hall C., Richards S. & Hillmen P. (2003) Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood 102, 35873591.
  • Hemker H.C. (2008) Recollections on thrombin generation. Journal of Thrombosis and Haemostasis 6, 219226.
  • Hemker H.C., Willems G.M. & Beguin S. (1986) A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thrombosis and Haemostasis 56, 917.
  • Hemker H.C., Wielders S., Kessels H. & Beguin S. (1993) Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thrombosis and Haemostasis 70, 617624.
  • Hemker H.C., Giesen P., Al Dieri R., Regnault V., de Smedt E., Wagenvoord R., Lecompte T. & Beguin S. (2003) Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiology of Haemostasis and Thrombosis 33, 415.
  • Ho W.K., Hankey G.J., Quinlan D.J. & Eikelboom J.W. (2006) Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Archives of Internal Medicine 166, 729736.
  • Hron G., Eichinger S., Weltermann A., Quehenberger P., Halbmayer W.M. & Kyrle P.A. (2006a) Prediction of recurrent venous thromboembolism by the activated partial thromboplastin time. Journal of Thrombosis and Haemostasis 4, 752756.
  • Hron G., Kollars M., Binder B.R., Eichinger S. & Kyrle P.A. (2006b) Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. Journal of the American Medical Association 296, 397402.
  • van Hylckama Vlieg A., van der Linden I.K., Bertina R.M. & Rosendaal F.R. (2000) High levels of factor IX increase the risk of venous thrombosis. Blood 95, 36783682.
  • van Hylckama Vlieg A., Baglin C.A., Bare L.A., Rosendaal F.R. & Baglin T.P. (2008) Proof of principle of potential clinical utility of multiple SNP analysis for prediction of recurrent venous thrombosis. Journal of Thrombosis and Haemostasis 6, 751754.
  • Kahn S.R., Shrier I., Julian J.A., Ducruet T., Arsenault L., Miron M.J., Roussin A., Desmarais S., Joyal F., Kassis J., Solymoss S., Desjardins L., Lamping D.L., Johri M. & Ginsberg J.S. (2008) Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Annals of Internal Medicine 149, 698707.
  • Kearon C. (2003) Natural history of venous thromboembolism. Circulation 107, I22I30.
  • Kearon C., Julian J.A., Kovacs M.J., Anderson D.R., Wells P., Mackinnon B., Weitz J.I., Crowther M.A., Dolan S., Turpie A.G., Geerts W., Solymoss S., van Nguyen P., Demers C., Kahn S.R., Kassis J., Rodger M., Hambleton J., Gent M. & Ginsberg J.S. (2008a) Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood 112, 44324436.
  • Kearon C., Kahn S.R., Agnelli G., Goldhaber S., Raskob G.E. & Comerota A.J. (2008b) Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(Suppl. 6), 454S545S.
  • Koster T., Blann A.D., Briet E., Vandenbroucke J.P. & Rosendaal F.R. (1995) Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345, 152155.
  • Kraaijenhagen R.A., in’t Anker P.S., Koopman M.M., Reitsma P.H., Prins M.H., van den Ende A. & Buller H.R. (2000) High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thrombosis and Haemostasis 83, 59.
  • Kyrle P.A., Minar E., Hirschl M., Bialonczyk C., Stain M., Schneider B., Weltermann A., Speiser W., Lechner K. & Eichinger S. (2000) High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. New England Journal of Medicine 343, 457462.
  • Langlois N.J. & Wells P.S. (2003) Risk of venous thromboembolism in relatives of symptomatic probands with thrombophilia: a systematic review. Thrombosis and Haemostasis 90, 1726.
  • Laporte S., Mismetti P., Decousus H., Uresandi F., Otero R., Lobo J.L. & Monreal M. (2008) Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry. Circulation 117, 17111716.
  • Legnani C., Cosmi B., Cini M., Frascaro M., Guazzaloca G. & Palareti G. (2004) High plasma levels of factor VIII and risk of recurrence of venous thromboembolism. British Journal of Haematology 124, 504510.
  • Legnani C., Mattarozzi S., Cini M., Cosmi B., Favaretto E. & Palareti G. (2006) Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal. British Journal of Haematology 134, 227232.
  • Luddington R. & Baglin T. (2004) Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition. Journal of Thrombosis and Haemostasis 2, 19541959.
  • Mann K.G., Brummel K. & Butenas S. (2003) What is all that thrombin for? Journal of Thrombosis Haemostasis 1, 15041514.
  • Marchiori A., Mosena L., Prins M.H. & Prandoni P. (2007) The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haematologica 92, 11071114.
  • Meijers J.C., Tekelenburg W.L., Bouma B.N., Bertina R.M. & Rosendaal F.R. (2000) High levels of coagulation factor XI as a risk factor for venous thrombosis. New England Journal of Medicine 342, 696701.
  • Morelli V.M., De Visser M.C., Vos H.L., Bertina R.M. & Rosendaal F.R. (2005) ABO blood group genotypes and the risk of venous thrombosis: effect of factor V Leiden. Journal of Thrombosis and Haemostasis 3, 183185.
  • Naess I.A., Christiansen S.C., Romundstad P., Cannegieter S.C., Rosendaal F.R. & Hammerstrom J. (2007) Incidence and mortality of venous thrombosis: a population-based study. Journal of Thrombosis and Haemostasis 5, 692699.
  • Palareti G., Manotti C., DAngelo A., Pengo V., Erba N., Moia M., Ciavarella N., Devoto G., Berrettini M., Leali N., Poggi M., Legnani C., Musolesi S. & Coccheri S. (1997) Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study: ISCOAT study group (Italian Study on Complications of Oral Anticoagulant Therapy). Thrombosis and Haemostasis 78, 14381443.
  • Palareti G., Legnani C., Cosmi B., Guazzaloca G., Pancani C. & Coccheri S. (2002) Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thrombosis and Haemostasis 87, 712.
  • Palareti G., Legnani C., Cosmi B., Valdre L., Lunghi B., Bernardi F. & Coccheri S. (2003) Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 108, 313318.
  • Palareti G., Legnani C., Cosmi B., Guazzaloca G., Cini M. & Mattarozzi S. (2005) Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence. Journal of Thrombosis and Haemostasis 3, 955961.
  • Palareti G., Cosmi B., Legnani C., Tosetto A., Brusi C., Iorio A., Pengo V., Ghirarduzzi A., Pattacini C., Testa S., Lensing A.W. & Tripodi A. (2006) D-dimer testing to determine the duration of anticoagulation therapy. New England Journal of Medicine 355, 17801789.
  • Pengo V., Lensing A.W., Prins M.H., Marchiori A., Davidson B.L., Tiozzo F., Albanese P., Biasiolo A., Pegoraro C., Iliceto S. & Prandoni P. (2004) Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. New England Journal of Medicine 350, 22572264.
  • Poli D., Antonucci E., Ciuti G., Abbate R. & Prisco D. (2007) Anticoagulation quality and the risk of recurrence of venous thromboembolism. Thrombosis and Haemostasis 98, 11481150.
  • Prandoni P., Hutten B.A., van Dongen C.J., Pesavento R. & Prins M.H. (2007) Quality of oral anticoagulant treatment and risk of subsequent recurrent thromboembolism in patients with deep vein thrombosis. Journal of Thrombosis and Haemostasis 5, 1555.
  • Reiner A.P., Lange L.A., Smith N.L., Zakai N.A., Cushman M. & Folsom A.R. (2009) Common hemostasis and inflammation gene variants and venous thrombosis in older adults from the Cardiovascular Health Study. Journal of Thrombosis and Haemostasis 7, 14991505.
  • Reitsma P.H. & Rosendaal F.R. (2007) Past and future of genetic research in thrombosis. Journal of Thrombosis and Haemostasis 5(Suppl 1), 264269.
  • Rosendaal F.R. (1999) Venous thrombosis: a multicausal disease. Lancet 353, 11671173.
  • Rosendaal F.R. & Bovill E.G. (2002) Heritability of clotting factors and the revival of the prothrombotic state. Lancet 359, 638639.
  • Rosendaal F.R., Cannegieter S.C., van der Meer F.J. & Briet E. (1993) A method to determine the optimal intensity of oral anticoagulant therapy. Thrombosis and Haemostasis 69, 236239.
  • Schulman S., Kearon C., Kakkar A.K., Mismetti P., Schellong S., Eriksson H., Baanstra D., Schnee J. & Goldhaber S.Z. (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine 361, 23422352.
  • Silverstein M.D., Heit J.A., Mohr D.N., Petterson T.M., O’Fallon W.M. & Melton L.J. III (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Archives of Internal Medicine 158, 585593.
  • Thuerlemann C., Haeberli A. & Alberio L. (2009) Monitoring thrombin generation by electrochemistry: development of an amperometric biosensor screening test for plasma and whole blood. Clinical Chemistry 55, 505512.
  • Tormene D., Simioni P., Pagnan A. & Prandoni P. (2004) The G20210A prothrombin gene mutation: is there room for screening families? Journal of Thrombosis and Haemostasis 2, 14871488.
  • Tripodi A., Chantarangkul V., Martinelli I., Bucciarelli P. & Mannucci P.M. (2004) A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. Blood 104, 36313634.
  • Tripodi A., Legnani C., Chantarangkul V., Cosmi B., Palareti G. & Mannucci P.M. (2008) High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. Journal of Thrombosis and Haemostasis 6, 13271333.
  • Tripodi A., Legnani C., Lemma L., Cosmi B., Palareti G., Chantarangkul V. & Mannucci P.M. (2010) Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism. Journal Thrombosis Thrombolysis 30, 215219.
  • Verhovsek M., Douketis J.D., Yi Q., Shrivastava S., Tait R.C., Baglin T., Poli D. & Lim W. (2008) Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Annals of Internal Medicine 149, 481490.
  • Weltermann A., Eichinger S., Bialonczyk C., Minar E., Hirschl M., Quehenberger P., Schonauer V. & Kyrle P.A. (2003) The risk of recurrent venous thromboembolism among patients with high factor IX levels. Journal of Thrombosis and Haemostasis 1, 2832.